Head-to-head evidence
Paliperidone (Invega) vs Risperidone (Risvan)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone (Invega)
Marketed by Johnson & Johnson
NCT00077714 · Phase 3 · completed
The study was randomized and double-blind, but it enrolled only 12 participants and the registry does not clearly identify a comparator arm. Its primary endpoint was a clinical symptom measure (PANSS), but whether it was met cannot be determined because results are not posted.
Next expected readout: September 2027 · NCT04478838 (registry estimate)
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone (Invega)'s landscape · Risperidone (Risvan)'s landscape